Updated 23:21 GMT, 4 Nov 2026 SPX 7,688.62 +1.58% NDX 28,437.17 +0.91% VIX 16.61 -20.26% GOLD 4,069.70 +3.28% CL 88.35 -8.05% BTC 80,381.15 +3.93%
NAS100 28,437 +0.91% S&P 7,689 +1.58% GOLD $4,070 +3.28% BTC $80,381 +3.93% VIX 16.61 −20.26% prices · as of 23:21 UTC · 4 Nov
Vol. II · No. 309Thursday, 5 November 2026
TTitan Protect
Case Studies · Earnings Echo

A Clean Beat From Pfizer, and It Holds Up to Our Screen.

Filed Wednesday 4 November 2026 · 00:12 UTC · Entry no. 133838 · scored against the close · never edited

A Clean Beat From Pfizer, and It Holds Up to Our Screen.
Earnings Review · 04 November 2026
The print
Revenue $15.03B. EPS $0.87 vs $0.74 expected.
How the market took it
On 2026-11-03 the shares closed at $30.00, -2.2% against the prior close of $30.67 (opening +0.0% from the prior close). Sellers faded the pop: 2.2 points of the opening gain were given back by the close, which says the first read was too generous. Option volatility implied a normal one-day swing of about ±1.7%, so a -2.2% close was larger than the market implied. Across the last 25 reports the shares have moved an average of +0.2% over the five sessions after the print, so the -2.2% on the day sits behind that average.
What changed versus going in
Earnings came in at $0.87 a share against $0.74 expected, a beat of 18% (+$0.13 a share). Revenue of $15.03B compares with $15.90B expected, 5.4% below consensus.
Did the flow confirm the move?
Underlying money flow reads as accumulation (21-day Chaikin Money Flow +0.15, five-day price change +3.0%, as of 2026-11-02, desk flow model).
Give the business its due
The business itself is genuinely strong: revenue growing about 3%, net margins near 7%, a narrow competitive moat, backed by a 5% return on equity.
Levels that matter
At $30.00 the shares sit 1% below the 52-week high of $30.44 and 27% above the low of $23.62 (94% of the way up the range). The 50-day average is $28.30, below the price. The 200-day average is $26.48, below the price.
The valuation lens
The shares trade about 16% below our fair-value estimate: a modest cushion. Fair value lands near $36 against a $30.00 share price, a margin of safety of about 16%. The trailing multiple sits around 39 times earnings, which only makes sense if the growth holds.
The ethical lens, our differentiator
Screens compliant (on our anchor standard; the faith-based screen is stricter here). A name values-conscious investors can weigh on the merits.
The verdict for a values-conscious investor
It clears the screen; size it to your own risk and conviction. One quarter, strong or soft, does not decide whether a holding is suitable.

This is analysis, not financial advice. Always manage your risk.

How This Entry Scores

Every level named in a session brief is scored against the next scheduled close. Nothing is edited after filing: if a level breaks, the record shows it as filed, not as corrected. The desk's full scored history sits on the track record page.

Continue Reading View all Case Studies →
Membership

The ledger is public. The desk behind it is not.

Membership opens every room and every entry the day it is filed, with the same dated honesty the record is built on.

Join the desk

This is analysis, not financial advice. Always manage your risk.

Get our weekly market brief free.